Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $2.5 million.

  • Heron Therapeutics' Change in Accured Expenses rose 17087.38% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 46353.64%. This contributed to the annual value of $330000.0 for FY2024, which is 10787.21% up from last year.
  • Per Heron Therapeutics' latest filing, its Change in Accured Expenses stood at $2.5 million for Q3 2025, which was up 17087.38% from -$1.2 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Change in Accured Expenses high stood at $13.5 million for Q4 2022, and its period low was -$7.7 million during Q4 2021.
  • For the 5-year period, Heron Therapeutics' Change in Accured Expenses averaged around $569631.6, with its median value being $520000.0 (2023).
  • In the last 5 years, Heron Therapeutics' Change in Accured Expenses soared by 27530.62% in 2022 and then crashed by 129768.79% in 2024.
  • Heron Therapeutics' Change in Accured Expenses (Quarter) stood at -$7.7 million in 2021, then surged by 275.31% to $13.5 million in 2022, then plummeted by 108.56% to -$1.2 million in 2023, then soared by 233.85% to $1.5 million in 2024, then skyrocketed by 62.84% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, -$1.2 million for Q2 2025, and $5.7 million during Q1 2025.